Market Overview

Lexicon Announces A Publication In The American Diabetes Association's Journal, Diabetes Care

Related LXRX
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs
Insider Buys Of The Week: AbbVie, Energen, NuStar And More
  • Results from Phase 2b Clinical Study in Patients with Type 2 Diabetes Provide Evidence that SGLT1 inhibition with LX4211 Provides a Clinically Meaningful Benefit

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced a publication in the online edition of the American Diabetes Association's journal, Diabetes Care, entitled, "Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, in Type 2 Diabetes on Metformin Monotherapy". The publication provided detailed results from the Phase 2b clinical study of LX4211 that Lexicon conducted in patients with type 2 diabetes. A complete copy of the publication can be found on Diabetes Care website at

"This peer-reviewed publication provides a detailed assessment of how, as dose escalated, LX4211 produced additional dose-dependent reductions in A1C in the absence of corresponding increases in urinary glucose excretion," said Dr. Brian Zambrowicz, Lexicon's executive vice president and chief scientific officer. "This provides further evidence that the SGLT1 inhibition by LX4211 produces a clinically meaningful benefit for patients with type 2 diabetes and further differentiates LX4211 as a first-in-class dual inhibitor of both SGLT1 and SGLT2."

In a double-blind, randomized, placebo-controlled, 12-week study in 299 patients with poorly controlled type 2 diabetes on metformin therapy, LX4211 provided a statistically significant reduction in A1C in a dose-dependent manner of 0.42% (75 mg once a day), 0.52% (200 mg once a day), 0.80% (200 mg twice a day), and 0.92% (400 mg once a day) as compared to a 0.09% reduction for placebo (p<0.001 for all doses). Greater A1C reductions were produced by the 400 mg once a day dose than the 200 mg once a day dose without higher urinary glucose excretion. In addition, LX4211 significantly reduced body weight by 1.85 kg (p<0.001) and systolic blood pressure by 5.7 mm Hg (p<0.001). Adverse events were generally mild to moderate and the overall incidence of adverse events with LX4211 was similar to placebo.

Posted-In: News FDA Press Releases


Related Articles (LXRX)

View Comments and Join the Discussion!

Vicon Names Eric Fullerton CEO And Director

Toyota Motor Corp's Relationship With Tesla Motors Inc Appears To Be Far From Over